Fulcrum Therapeutics Intrinsic Value Calculator – FULCRUM THERAPEUTICS Reports Positive Earnings Results for Third Quarter of FY2023
November 21, 2023
☀️Earnings Overview
FULCRUM THERAPEUTICS ($NASDAQ:FULC) reported their earnings results for the third quarter of FY2023 on November 7 2023. The total revenue was USD 0.8 million, which was 35.6% lower than the comparable period of the preceding year. Net income for the reported quarter was USD -24.0 million, a slight decrease from the -23.7 million reported in the year prior.
Share Price
The stock opened at $3.7 and closed at $4.3, soaring by 19.5% from its prior closing price of $3.6. The strong performance of FULCRUM THERAPEUTICS has been driven by its increased focus on developing innovative therapeutic solutions for rare diseases. The company has made significant progress in developing a number of treatments that have been approved by various regulatory bodies around the world, and many more are currently in development.
These positive earnings results have left investors optimistic about FULCRUM THERAPEUTICS’ future prospects and the stock is expected to continue its strong performance in the coming quarters. With its continued focus on developing innovative treatments for rare diseases, FULCRUM THERAPEUTICS is well-positioned to capitalize on the growing demand for such therapies and generate long-term value for its shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Fulcrum Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 2.62 | -98.71 | -3770.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Fulcrum Therapeutics. More…
| Operations | Investing | Financing |
| -87.5 | -91.41 | 118.05 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Fulcrum Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 278.88 | 23.42 | 4.13 |
Key Ratios Snapshot
Some of the financial key ratios for Fulcrum Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -17.1% | – | -4226.2% |
| FCF Margin | ROE | ROA |
| -3362.0% | -26.1% | -24.8% |
Analysis – Fulcrum Therapeutics Intrinsic Value Calculator
At GoodWhale, we have conducted an analysis of FULCRUM THERAPEUTICS‘ fundamentals. After our review, we have determined that the company’s intrinsic value is around $9.2, which was calculated using our proprietary Valuation Line. The current stock price stands at $4.3 which is undervalued by 53.3%. This means that the stock represents a potential buying opportunity for investors. More…
Peers
The company has three main competitors: Kinnate Biopharma Inc, Arcus Biosciences Inc, and Pardes Biosciences Inc. All three companies are focused on the development of treatments for rare and serious diseases.
– Kinnate Biopharma Inc ($NASDAQ:KNTE)
Kinnate Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company has a market cap of $384.51 million and a negative return on equity of 27.29%. Kinnate is developing a portfolio of small molecule drugs that target cancer metabolism and the tumor microenvironment. The company’s lead product candidate is Kinna-292, a novel small molecule inhibitor of glutaminase, which is in Phase I clinical trials for the treatment of solid tumors. Kinnate is also developing KB-0786, a small molecule inhibitor of fatty acid synthase, which is in preclinical development for the treatment of breast cancer.
– Arcus Biosciences Inc ($NYSE:RCUS)
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on developing and commercializing cancer immunotherapies. The company’s market cap is $2 billion and its ROE is 5.73%. Arcus Biosciences is headquartered in Hayward, California.
– Pardes Biosciences Inc ($NASDAQ:PRDS)
Pardes Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to treat patients with serious and life-threatening diseases. The company’s lead product candidate is PARD-302, a first-in-class, oral small molecule inhibitor of the protease-activated receptor-1 (PAR1), which is in development for the prevention and treatment of thrombosis, including venous thromboembolism (VTE) and atrial fibrillation (AF). Pardes Biosciences Inc. has a market cap of $77.9 million as of 2022.
Summary
FULCRUM THERAPEUTICS recently released their Q3 FY2023 earnings report, indicating a total revenue of $0.8 million, representing a 35.6% decrease from the same period in the previous year. Net income was reported to be -$24 million, only slightly down from the -$23.7 million reported the previous year. Despite this underwhelming financial performance, the stock price has seen an increase on the day of the report’s release. Investors should consider the company’s long-term prospects, its ability to contain expenses and generate profits, and its potential for growth before investing in FULCRUM THERAPEUTICS.
Related Posts
Recent Posts
